SV2006002166A - Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674 - Google Patents

Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674

Info

Publication number
SV2006002166A
SV2006002166A SV2005002166A SV2005002166A SV2006002166A SV 2006002166 A SV2006002166 A SV 2006002166A SV 2005002166 A SV2005002166 A SV 2005002166A SV 2005002166 A SV2005002166 A SV 2005002166A SV 2006002166 A SV2006002166 A SV 2006002166A
Authority
SV
El Salvador
Prior art keywords
ref
kits
contraceptive
regimes
progesterone
Prior art date
Application number
SV2005002166A
Other languages
English (en)
Inventor
Gary Sondermann Grubb
Ginger Dale Constantine
Andrew Fensome
Casey Cameron Mccomas
Edward George Melenski
Michael Anthony Marella
Jay E Wrobel
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35106665&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2006002166(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SV2006002166A publication Critical patent/SV2006002166A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SSE PROVEE UN MÉTODO DE ANTICONCEPCIÓN QUE INCLUYE LA ADMINISTRACIÓN DE 21 A 27 DÍAS CONSECUTIVOS DE UNO O MÁS ANTAGONISTAS DE RP EN AUSENCIA DE UNA PROGESTINA, ESTRÓGENO U OTRO COMPUESTO ESTEROIDE, SEGUIDO DE 1 A 7 DÍAS SIN NINGÚN AGENTE ACTIVO. SE DESCRIBE, ADEMÁS, UN KIT DESDE EL PUNTO DE VISTA FARMACÉUTICO PARA FACILITAR LA ADMINISTRACIÓN DE ESTE RÉGIMEN.
SV2005002166A 2004-07-07 2005-07-06 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674 SV2006002166A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58588304P 2004-07-07 2004-07-07
US67613505P 2005-04-29 2005-04-29

Publications (1)

Publication Number Publication Date
SV2006002166A true SV2006002166A (es) 2006-05-09

Family

ID=35106665

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2005002166A SV2006002166A (es) 2004-07-07 2005-07-06 Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674

Country Status (20)

Country Link
US (1) US20060009509A1 (es)
EP (1) EP1773323A1 (es)
JP (1) JP2008505906A (es)
KR (1) KR20070039912A (es)
AR (1) AR049664A1 (es)
AU (1) AU2005271974A1 (es)
BR (1) BRPI0512993A (es)
CA (1) CA2571198A1 (es)
CR (1) CR8800A (es)
EC (1) ECSP077131A (es)
GT (1) GT200500186A (es)
IL (1) IL180238A0 (es)
MX (1) MXPA06014580A (es)
NO (1) NO20070377L (es)
PA (1) PA8638501A1 (es)
PE (1) PE20060485A1 (es)
RU (1) RU2006144069A (es)
SV (1) SV2006002166A (es)
TW (1) TW200605880A (es)
WO (1) WO2006017075A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
JP5288796B2 (ja) 2004-07-07 2013-09-11 ワイス・エルエルシー 周期的プロゲスチンレジメン及びキット
PT1768625E (pt) 2004-07-09 2011-04-18 Hra Pharma Lab Composições de libertação sustida contendo moduladores do receptor da progesterona
GT200500185A (es) * 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
MY145694A (en) 2005-04-11 2012-03-30 Xenon Pharmaceuticals Inc Spiroheterocyclic compounds and their uses as therapeutic agents
MY144968A (en) 2005-04-11 2011-11-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their uses as therapeutic agents
WO2008060789A2 (en) 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
SG10201703086VA (en) 2008-10-17 2017-05-30 Xenon Pharmaceuticals Inc Spiro-oxindole compounds and their use as therapeutic agents
EP2350091B1 (en) 2008-10-17 2015-06-03 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
JP5951480B2 (ja) 2009-04-14 2016-07-13 ラボラトワール・アシュエールア−ファルマＬａｂｏｒａｔｏｉｒｅ Ｈｒａ−Ｐｈａｒｍａ オンデマンド避妊方法
EA201190287A1 (ru) 2009-06-18 2012-06-29 Пфайзер Инк. Бициклические и трициклические соединения в качестве ингибиторов kat ii
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
RU2544852C2 (ru) 2009-10-14 2015-03-20 Ксенон Фармасьютикалз Инк. Способы синтеза спиро-оксиндольных соединений
US9504671B2 (en) 2010-02-26 2016-11-29 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
US9375437B2 (en) * 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
EP2646443B1 (en) 2010-12-01 2014-09-24 Pfizer Inc Kat ii inhibitors
US8951996B2 (en) 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
EP2968367A1 (en) * 2013-03-14 2016-01-20 Laboratoire HRA Pharma Method for scheduling ovulation
TW201636017A (zh) 2015-02-05 2016-10-16 梯瓦製藥國際有限責任公司 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法
MX2017016823A (es) 2015-06-22 2018-03-12 Lipocine Inc Composiciones orales que contienen éster de 17- hydroxiprogesterona y métodos relacionados.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6444668B1 (en) * 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors

Also Published As

Publication number Publication date
IL180238A0 (en) 2007-07-04
NO20070377L (no) 2007-02-07
US20060009509A1 (en) 2006-01-12
AR049664A1 (es) 2006-08-23
GT200500186A (es) 2006-03-02
WO2006017075A1 (en) 2006-02-16
PE20060485A1 (es) 2006-06-24
AU2005271974A1 (en) 2006-02-16
TW200605880A (en) 2006-02-16
ECSP077131A (es) 2007-02-28
EP1773323A1 (en) 2007-04-18
PA8638501A1 (es) 2006-07-03
CA2571198A1 (en) 2006-02-16
KR20070039912A (ko) 2007-04-13
RU2006144069A (ru) 2008-08-20
BRPI0512993A (pt) 2008-04-22
CR8800A (es) 2007-08-28
JP2008505906A (ja) 2008-02-28
MXPA06014580A (es) 2007-03-23

Similar Documents

Publication Publication Date Title
SV2006002166A (es) Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits ref. am101674
SV2006002165A (es) Regimenes y kits de progestina ciclica ref. am101677
PA8508701A1 (es) Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco
AR048878A1 (es) Composiciones topicas de metadona y metodos para usarlas
PE20061016A1 (es) Una formulacion solida de dosificacion farmaceutica
AR034787A1 (es) Dispositivo de liberacion de droga que contiene oseltamivir y un antagonista h1
CR6210A (es) Composiciones de celecoxib
BRPI0315315B8 (es)
ECSP088240A (es) Composición de trazodona para administración una vez por día
AR058308A1 (es) Fragmentos vip y metodos de uso de los mismos
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
DK1408981T3 (da) Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler
UY28007A1 (es) Tratamiento terapeutico
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
PE20211199A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
DE60301261D1 (de) Pharmazeutische zusammensetzungen enthaltend 17alpha-furanylester von 17beta-carbothioat androstanderivaten und einen muskarinrezeptorantagonist
CO5200833A1 (es) Regimenes de dosificacion para lasofoxifeno
BRPI0517983A (pt) uso de corticosteróide em associação com diurético e antiácido para tratamento de estenose vascular e prevenção de reestenose vascular
CL2004001317A1 (es) Composicion farmaceutica que comprende el antagonista de receptores de progesterona 11b-(4-acetilfenil)-17b-hidroxi-17 alfa-(1,1,2,2,2-pentafluoroetil)-estra-4,9-dien-3-ona y un antiestrogeno puro; y su uso para tratar una enfermedad dependiente de h
SV2006002224A (es) Composicion farmaceutica ref. bhco41368-sv
SV2006002225A (es) Composicion farmaceutica ref. bhco41367-sv
BRPI0510906A (pt) composição farmacêutica tópica, composição para administração tópica e seu uso
BRPI0511253A (pt) composição farmacêutica
刘晓敏 A Study on Self and Others in the Japanese History Textbooks of the 1980-90

Legal Events

Date Code Title Description
FD Lapse